Asmita N. Mishra

Hematology
12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 156 publications

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Journal: Blood advances
Published: April 08, 2026

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Journal: Blood advances
Published: March 25, 2026

EDA-OCBLS: An error-distribution aware one-class broad learning system for anomaly detection.

EDA-OCBLS: An error-distribution aware one-class broad learning system for anomaly detection.

Journal: Neural networks : the official journal of the International Neural Network Society
Published: January 14, 2026

Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT).

Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT).

Journal: Bone marrow transplantation
Published: January 13, 2026

CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.

CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.

Journal: Blood advances
Published: September 08, 2025

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

Journal: Blood advances
Published: September 08, 2025

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia.

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia.

Journal: Transplantation and cellular therapy
Published: July 27, 2025

Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes.

Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes.

Journal: Blood advances
Published: July 11, 2025

Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.

Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.

Journal: Blood advances
Published: July 11, 2025

Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes.

Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes.

Journal: Blood advances
Published: July 11, 2025

Expanded antigen-specific donor regulatory T cells for GVHD prevention.

Expanded antigen-specific donor regulatory T cells for GVHD prevention.

Journal: Blood
Published: July 02, 2025

Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.

Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.

Journal: Bone marrow transplantation
Published: April 03, 2025
Showing 1-12 of 156

Last Updated: 09/26/2026